Articles by : Crypto News & Expert Market Analysis

Samsung Biologics targets peptides with $1.8 billion cash deal for PolyPeptide Group

Samsung Biologics plans to acquire Spain-based peptide CDMO PolyPeptide Group for $1.8 billion in cash to enter the fast-growing peptide-drug segment. Separately, Argenx agreed to buy Forte Biosciences in a $2.2 billion deal. In Europe, Catalyxx will receive €22 million in EU support to build a bio-alcohol plant in Portugal, while Eurodia Industrie said revenue rose from $39 million in 2023 to $91 million in 2025 on demand tied to industrial decarbonization. The developments are closely watched for what they could signal about growth prospects in the biopharmaceutical arm of Samsung Biologics’ parent, Samsung Electronics.

4h ago

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.

Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.